ClinicalTrials.gg
TerminatedNCT02315781Updated May 14, 2018

tDCS in Parkinson's Disease With Depression

An interventional study of active tDCS and Sham tDCS in Depression and Parkinson's, sponsored by Pacific Parkinson's Research Centre. Terminated at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-05-14.

Sponsored by Pacific Parkinson's Research Centre · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Resources to conduct study withdrawn

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 533 studies in Depression with a site in Canada — 107 open to participants now, 124 under way, 7 of them phase 3. Depression · Canada.

Enrollment
479th of 488
3 · median 77
Started
2015
with 16 others
No phase
334 of 533
78 open now
Registered
161st of 533
by date

Among the 533 studies in Depression with a site in Canada, this one is the 479th largest by enrollment of the 488 interventional ones that give a count, is one of 17 that started in 2015, is one of 334 with no phase, and was the 161st registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

107 of the 533 studies in Depression with a site in Canada are open now. Recruiting first, the newest first:

102 more — sign in →

All 107 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 533 studies in Depression with a site in Canada, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a progressive neurological disease that has effects on both movement and mental health. One of the most common mental health complications of PD is depression. Up to 30% of Parkinson's patients will experience depression at some point. We aim to investigate whether transcranial direct current stimulation (tDCS), a type of electrical stimulation for the brain, can improve depression in PD as well as improve motor function in PD.

Read the detailed description

The purpose of this double-blind, randomized control design study is to investigate the efficacy of 15-sessions of tDCS (versus 15-sessions of sham tDCS) to treat depression in PD. We will also assess dopamine function in a smaller cohort of participants before and after their 15 sessions of tDCS by using PET scanning.

03

Conditions studied

  • Depression
  • Parkinson's
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. are outpatients,
  2. are voluntary and competent to consent to treatment,
  3. have a Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of major depressive disorder (MDD),
  4. have a diagnosis of PD according to the UK PD brain bank criteria,
  5. are 19 years of age or more,
  6. have a score > 13 on the Beck Depression Inventory-II (BDI-II),
  7. still have depressive symptoms after 6 weeks or more of antidepressant (SSRI) medication treatment (and on a stabilized dose of at least 4 weeks),
  8. are able to adhere to the treatment schedule,
  9. are proficient in written and verbal English.

Exclusion Criteria:

  1. have a history of substance dependence or abuse within the last 6 months,
  2. have a concomitant significant unstable medical illness,
  3. have active suicidal intent,
  4. have any history of seizure or medication-resistant epilepsy in the family,
  5. have a lifetime Mini-International Neuropsychiatric Interview (MINI) diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms
  6. have a MINI diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary and causing greater impairment than MDD,
  7. have failed a course of ECT in the current episode or previous episode,
  8. have received tDCS or other neurostimulation therapy for any previous indication due to the potential compromise of expectancy effects,
  9. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 5 minutes, or developmental disorder,
  10. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed,
  11. are taking a non-SSRI antidepressant medication,
  12. are pregnant (women of childbearing age only).

Exclusion Criteria for PET:

  1. unable to tolerate staying off anti-parkinsonian medication for 12-18 hours pre-PET scan,
  2. have a history of radiation therapy treatment or other high amounts of radiation.

Exclusion Criteria for MRI:

  • Artificial heart valve;
  • Brain aneurysm clip;
  • Electrical stimulator for nerves or bones;
  • Ear or eye implant;
  • Implanted drug infusion pump;
  • Coil, catheter, or filter in any blood vessel;
  • Orthopedic hardware (artificial joint, plate, screws);
  • Other metallic prostheses;
  • Shrapnel, bullets, or other metal fragments;
  • Surgery or tattoos (including tattooed eyeliner) in the last six weeks.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Active tDCS

    active tDCS will be used on half of the study participants

    Device: active tDCS

  • Sham comparator
    Sham tDCS

    Sham tDCS will be used on half of the study participants

    Device: Sham tDCS

Interventions

  • Deviceactive tDCS

    transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain

  • DeviceSham tDCS

    Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.

06

What researchers measure

Primary outcomes

  1. HAMD score

    an assessment of the severity of depression

    Time frame: 12 weeks

Secondary outcomes

  1. Dopamine levels

    PET scanning will be used to assess dopamine levels before and after sham/active tDCS in 20 participants

    Time frame: 12 weeks

07

Study locations

1 site
  • Pacific Parkinson's Research Centre
    Vancouver, British Columbia V6T 2B5, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2014
First posted
Dec 12, 2014
Start
Jan 2015
Primary completionActual
Dec 6, 2017
CompletionActual
Dec 6, 2017
Last update
May 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02315781
Lead sponsor
Pacific Parkinson's Research Centre
Responsible party
A. Jon Stoessl (Co-Director of the Centre for Brain Health UBC, Pacific Parkinson's Research Centre) — Principal investigator
First posted
Dec 12, 2014
Start date
Jan 2015
Primary completion
Dec 6, 2017
Completion
Dec 6, 2017
Last update
May 14, 2018

Study contacts

A.J Stoessl, MD
principal investigator · Pacific Parkinson's Research Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion